<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is an aggressive B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, with a characteristic clinical presentation, <z:mp ids='MP_0000002'>morphology</z:mp> and immunophenotype </plain></SENT>
<SENT sid="1" pm="."><plain>Over the past years, the typical translocation t(8;14) and its variants have been considered the molecular hallmark of this <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases with no detectable MYC rearrangement have been identified </plain></SENT>
<SENT sid="3" pm="."><plain>Intriguingly, these cases express MYC at levels comparable with cases carrying the translocation </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> cells c-Myc expression is tightly regulated through a complex feedback loop mechanism </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, MYC is often dysregulated, commonly due to genomic abnormalities </plain></SENT>
<SENT sid="6" pm="."><plain>It has recently emerged that this phenomenon may rely on an alteration of post-transcriptional regulation mediated by microRNAs (miRNAs), whose functional alterations are associated with <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>It is also emerging that c-Myc modulates miRNA expression, revealing an intriguing crosstalk between c-Myc and miRNAs </plain></SENT>
<SENT sid="8" pm="."><plain>PRINCIPAL FINDINGS: Here, we investigated the expression of miRNAs possibly regulated by c-Myc in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases positive or negative for the translocation </plain></SENT>
<SENT sid="9" pm="."><plain>A common trend of miRNA expression, with the exception of hsa-miR-9*, was observed in <z:hpo ids='HP_0000001'>all</z:hpo> of the cases </plain></SENT>
<SENT sid="10" pm="."><plain>Intriguingly, down-regulation of this miRNA seems to specifically identify a particular subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases, lacking MYC translocation </plain></SENT>
<SENT sid="11" pm="."><plain>Here, we provided evidence that hsa-miR-9-1 gene is heavily methylated in those cases </plain></SENT>
<SENT sid="12" pm="."><plain>Finally, we showed that hsa-miR-9* is able to modulate E2F1 and c-Myc expression </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Particularly, this study identifies hsa-miR-9* as potentially relevant for <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases with no detectable MYC translocation </plain></SENT>
<SENT sid="14" pm="."><plain>Deregulation of hsa-miR-9* may therefore be useful as a diagnostic tool, suggesting it as a promising novel candidate for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell marker </plain></SENT>
</text></document>